A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

Juan Gaztanaga; Michael Farkouh; James H.F. Rudd; Tilmann M. Brotz; David Rosenbaum; Venkatesh Mani; Todd C. Kerwin; Rebecca Taub; Jean-Claude Tardif; Ahmed Tawakol; Zahi A. Fayad

doi:10.1016/j.atherosclerosis.2015.02.027

A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

Atherosclerosis ◽

10.1016/j.atherosclerosis.2015.02.027 ◽

2015 ◽

Vol 240 (1) ◽

pp. 53-60 ◽

Cited By ~ 34

Author(s):

Juan Gaztanaga ◽

Michael Farkouh ◽

James H.F. Rudd ◽

Tilmann M. Brotz ◽

David Rosenbaum ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Vascular Inflammation ◽

Controlled Study ◽

Phase 2 ◽

Lipoxygenase Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome

Download Full-text

Impact of Prevention of DEpression in Patients with Acute Coronary Syndrome on CARDiac risk profile (DECARD): A double-blind, placebo-controlled study of escitalopram

International Journal of Cardiology ◽

10.1016/j.ijcard.2007.03.038 ◽

2007 ◽

Vol 119 ◽

pp. S14-S15

Author(s):

Jamal A. Hanash

Keyword(s):

Acute Coronary Syndrome ◽

Cardiac Risk ◽

Risk Profile ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome

Download Full-text

Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study

American Heart Journal ◽

10.1016/j.ahj.2004.07.041 ◽

2005 ◽

Vol 149 (3) ◽

pp. 451-457 ◽

Cited By ~ 55

Author(s):

Stella M. Macin ◽

Eduardo R. Perna ◽

Eduardo F. Farías ◽

Valeria Franciosi ◽

Jorge R. Cialzeta ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome ◽

Anti Inflammatory ◽

Inflammatory Effect

Download Full-text

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

American Heart Journal ◽

10.1016/j.ahj.2011.01.026 ◽

2011 ◽

Vol 161 (5) ◽

pp. 815-821.e6 ◽

Cited By ~ 63

Author(s):

C. Michael Gibson ◽

Jessica L. Mega ◽

Paul Burton ◽

Shinya Goto ◽

Freek Verheugt ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Standard Therapy ◽

Cardiovascular Events ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome

Download Full-text

Faculty Opinions recommendation of Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13931968.15387072 ◽

2012 ◽

Author(s):

Michael Fisch

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Malignant Ascites ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047281.793481249 ◽

2013 ◽

Author(s):

Jim Tsaltas

Keyword(s):

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Trials ◽

10.1186/1745-6215-10-20 ◽

2009 ◽

Vol 10 (1) ◽

Cited By ~ 13

Author(s):

Baiba Hedegaard Hansen ◽

Jamal Abed Hanash ◽

Alice Rasmussen ◽

Jørgen Fischer Hansen ◽

Morten Birket-Smith

Keyword(s):

Acute Coronary Syndrome ◽

Controlled Study ◽

Double Blind ◽

Coronary Syndrome

Download Full-text

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(17)30305-3 ◽

2017 ◽

Vol 5 (10) ◽

pp. 785-794 ◽

Cited By ~ 79

Author(s):

Hossein-Ardeschir Ghofrani ◽

Gérald Simonneau ◽

Andrea M D'Armini ◽

Peter Fedullo ◽

Luke S Howard ◽

...

Keyword(s):

Pulmonary Hypertension ◽

Chronic Thromboembolic Pulmonary Hypertension ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Thromboembolic Pulmonary Hypertension

Download Full-text

P.577 ADVANCE: phase 2, randomised, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with negative symptoms of schizophrenia

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2020.09.423 ◽

2020 ◽

Vol 40 ◽

pp. S328-S329

Author(s):

D. Bugarski-Kirola ◽

C. Arango ◽

M. Fava ◽

H. Nasrallah ◽

I.Y. Liu ◽

...

Keyword(s):

Negative Symptoms ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase 2, Randomized, Double-Blind, Placebo Controlled Study of Inecaclcitol Combined with Decitabine versus Decitabine: A New Treatment Strategy for Elderly AML Patients Unfit for Intensive Chemotherapy

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.059 ◽

2017 ◽

Vol 17 ◽

pp. S279

Author(s):

Olivier Hermine ◽

Jean Francois Dufour-Lamartinie ◽

Stephanie Renaux ◽

Jorge Cortes

Keyword(s):

Treatment Strategy ◽

Controlled Study ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Elderly Aml ◽

New Treatment

Download Full-text

JKB-122 in subjects with non-alcoholic fatty liver disease (NAFLD): a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study

Journal of Hepatology ◽

10.1016/s0168-8278(20)30779-0 ◽

2020 ◽

Vol 73 ◽

pp. S133

Author(s):

Kuo-Chin Huang ◽

Ming-Yao Chen ◽

Chih-Lin Lin ◽

Sien-Sing Yang ◽

Chao-Wei Hsu ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Multiple Dose ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Alcoholic Fatty Liver ◽

Double Blind Placebo ◽

Alcoholic Fatty Liver Disease

Download Full-text